

PSJ3

Exhibit 324

To: Matthew Benkert [Matthew.Benkert@tevapharm.com]
From: Colleen McGinn
Sent: Tue 4/2/2013 12:21:18 AM
Importance: Normal
Subject: Re: DEA Holds This Afternoon
Received: Tue 4/2/2013 12:21:18 AM

Thanks

Sent from my BlackBerry Wireless Handheld

From: Matthew Benkert
Sent: Monday, April 01, 2013 08:09 PM
To: Colleen McGinn
Subject: RE: DEA Holds This Afternoon

Not a problem. Just want to make sure the program doesn't stall and keeps moving forward. Let me know if you need any help going though that stuff and determining what we have and where we are at.



Matthew Benkert, PCI Diversion Investigator II
Tel: (215) 293-6596 Cell: (267) 247-6369 Fax: (215) 997-0925
Matthew.Benkert@tevapharm.com www.tevapharm.com

From: Colleen McGinn
Sent: Monday, April 01, 2013 8:03 PM
To: Matthew Benkert; Michael Edwards
Cc: Timothy Aleman
Subject: Re: DEA Holds This Afternoon

Matt,

Thanks for reviewing the orders. I really appreciate the support from you and Tim.

I would continue to use the criteria laid out by Kevin in his email. If you are uncomfortable with any part of the advice he's given, let me know.

I have to go through Kevin's files to see where we are, but we seemed to be at a pretty good stopping point right now.

Thanks again for your help.

Colleen

Sent from my BlackBerry Wireless Handheld

From: Matthew Benkert
Sent: Monday, April 01, 2013 07:53 PM
To: Colleen McGinn; Michael Edwards
Cc: Timothy Aleman
Subject: FW: DEA Holds This Afternoon

Colleen & Mike,

Case: 1:17-md-02804-DAP Doc #: 2350-1 Filed 08/14/19 Page 7 of 7
Below is some criteria that Kevin had developed regarding the Big 4. We would follow up now and confirm is still the criteria you would like us to use going forward, or is there part or all of this you would like to see modified? Besides the daily order review & releases is there any other current in progress SOM initiatives that need to be worked on / followed up on?



Matthew Benkert, PCI Diversion Investigator II
Tel: (215) 293-6596 Cell: (267) 247-6369 Fax: (215) 997-0925
Matthew.Benkert@tevapharm.com www.tevapharm.com

From: Kevin Kreutzer
Sent: Thursday, February 28, 2013 9:44 AM
To: Matthew Benkert
Cc: Michael Edwards; Timothy Aleman
Subject: RE: DEA Holds This Afternoon

Matt, Mike and Tim:

In regards to your questions:

Are we evaluating orders from the Big 4 differently than the rest?

- Yes, I am not scrutinizing the Big 4 as closely as the secondary distributors and retail pharmacy chains. We all know

The criteria I have been using in evaluating orders is:

Is the order for the Big 4?

- If yes, then I still look at their purchase history in BI (it's much more accurate than using Oracle for purchase history)
- I look at purchase history for the last 12 months, you can see the quantities of what the customer ordered in the int
- I also look at the "Current Monthly Oracle UCL and the "Current Monthly BI UCL". The BI UCL is a good tool to us
- I also use BI for every customer, not just the Big 4.

NDC	Product Description	Customer	Customer Number	DEA Item Group	Controlled Drug Schedule	DEA Number	Ship To Location Number	Ship To Location City	Customer Site Name	MIN	MAX	AVG	C
00555-0033-05	CHLORDIAZEPOXIDE HCL CAPSULES 10MG 1000	CARDINAL HEALTH	35021	C4F	IV	RC0314891	88567	GROVEPORT	5995 COMMERCE CENTER DR	36	648	203	1

If an order violates one UCL but not the others, is that enough to release?

- It depends on:
Is it a High Risk Item? For the Big 4?

Which is: **Actiq, Adderall, Adipex, Buprenorphine, Clonazepam, Dexmethylphenidate, Dextroamphetamine, Diaz**
If it is, then I will look at their purchase history in BI and look for trends, if it is consistent with their history and only exce
Again, I look at the Current monthly or quarterly UCL in BI and to make sure it is consistent with the UCL's we have set

- If the order is for a secondary or retail pharmacy chain and is a high risk item:
I'll look at their purchase history to see if it is consistent with purchases for the last 12 months. If it is not, then contact Cust

When do you want us to request additional information?

If the order is not consistent with a customer's purchase history and you don't feel comfortable releasing the order, contact purchases so to avoid repeating inquiries on the same customers.

How far back in a customer's order history are we going for justifications?

I go back 12 months, I feel 24 months does not give you an accurate purchase history since business models change.

What percentage over the UCL are you comfortable with releasing?

I am still using the 10 percent rule give or take a couple percentage points.


-If an order needs further clarification from the customer, do we still notify customer service to handle that?

Yes, customer service contacts the customer. To avoid going back and forth with Customer Service in getting accurate and

In the orders below, the first things I notice right away is:

- Big 4 customers
- No products are high risk items
- Acetaminophen & Codeine are seasonal products (used for the bad flu season we had). I do suspect that orders for this p

Any other questions, please let me know.





Kevin Kreutzer Manager, Diversion SOM
 Tel: 267-468-4346 Cell: 215-859-3371
 Kevin.Kreutzer@tevapharm.com
 www.tevapharm.com

From: Matthew Benkert
Sent: Wednesday, February 27, 2013 7:17 PM
To: Kevin Kreutzer
Cc: Michael Edwards; Timothy Aleman
Subject: RE: DEA Holds This Afternoon

Kevin,

There were 5 holds in Oracle tonight. All were for different ABC locations. Three of the holds have been released but there are two highlighted below I think you need to look at and make a decision on. These are probably good to go and just need the UCL adjusted. Order #799810 says that you already adjusted the Quarterly UCL on the last order and now they are over again. Order #799743 has exceeded the monthly UCL by 144 pieces.

Can you also provide Mike, Tim and I with some guidance on what your criteria is when reviewing, evaluating and releasing these orders moving forward. One of the biggest things I think you will agree with, is that we all need to make sure we are consistent in the way we evaluate and release orders. If you could let us know how you are now looking at these now, such as:

- Are we evaluating orders from the big 4 differently than the rest?
- If an order violates one UCL but not the others, is that enough to release?
- When do you want us to request additional information?
- How far back in a customer's order history are we going for justifications?
- What percentage over the UCL are you comfortable with releasing?
- If an order needs further clarification from the customer, do we still notify customer service to handle that?

Thanks for the clarification. I just don't want to be operating outside the parameters of your program. Thanks.

799743	AMERISOURCEBERGEN DRUG CORP	00555-0159-02	144	2/27/2013 14:37	53420	Custom Order Q Control
799736	AMERISOURCEBERGEN DRUG CORP	00093-0130-01	24	2/27/2013 14:36	53436	This ord pattern.
799690	AMERISOURCEBERGEN DRUG CORP	00093-5269-01	48	2/27/2013 14:29	53442	This ord pattern.
799679	AMERISOURCEBERGEN DRUG CORP	00555-0159-04	72	2/27/2013 14:27	111474	This ord pattern.
799810	AMERISOURCEBERGEN DRUG CORP	00555-0974-02	24	2/27/2013 18:05	115770	Custom Quarterl Quarterl

TEVA

Matthew Benkert, PCI Diversion Investigator II
Tel: (215) 293-6596 Cell: (267) 247-6369 Fax: (215) 997-0925
Matthew.Benkert@tevapharm.com www.tevapharm.com

From: Kevin Kreutzer
Sent: Wednesday, February 27, 2013 1:18 PM
To: Matthew Benkert
Cc: Michael Edwards
Subject: DEA Holds This Afternoon

I am leaving at 3:30pm today for an appointment, could you check customer orders after I leave?

Thanks,

TEVA

Kevin Kreutzer Manager, Diversion SOM
Tel: 267-468-4346 Cell: 215-859-3371
Kevin.Kreutzer@tevapharm.com
www.tevapharm.com